Xue Xiali, Yang Xinwei, Shi Xiubo, Deng Zhongyi
School of Sports Medicine and Health, Chengdu Sport University, Chengdu, China.
Hospital of Chengdu Office of People's Government of Tibetan Autonomous Region, Chengdu, China.
Clin Transl Allergy. 2023 Jul;13(7):e12283. doi: 10.1002/clt2.12283.
Atopic dermatitis (AD) is a prevailing skin disease in childhood. Several studies have appraised probiotics as a strategy for treating AD. We aimed to assess the validity of probiotics in the treatment of AD in children.
We systematically searched the PubMed/MEDLINE, Embase, Scopus, EBSCO, Web of Science and Cochrane library databases for randomized controlled trials (RCTs) that assessed the effect of probiotic treatment on SCORAD value in pediatric patients with AD compared with a placebo group between 1 January 2010 and 1 January 2023. The risk of bias and the certainty of evidence were assessed using Cochrane ROB 2.0.
A total of 10 outcomes from 9 RCTs involving 1000 patients were included. Three of these outcomes were analyzed as dichotomous variables in 373 patients. The other seven were analyzed for continuous variables in 627 patients. A meta-analysis of the random-effect model of the dichotomous variables demonstrated no significant difference between the probiotic and control groups [OR = 1.75, 95% confidence interval (CI) (0.70, 4.35), p = 0.23, I = 68%]. A meta-analysis of the random-effect model of continuous variables demonstrated significant differences between the probiotic and control groups [MD = -4.24, 95% CI (-7.78, -0.71), p = 0.002, I = 71%]. Subgroup analysis of continuous variables showed that the effects of children's age, treatment duration and probiotic species on the SCORAD value were not statistically significant.
Evidence on the improvement effect of probiotics on pediatric patients with AD is limited. This study showed that single-strain probiotic treatment exerts a positive effect on AD. Restricted to the quantity and quality of incorporated studies, these conclusions have yet to be validated by high-quality studies.
特应性皮炎(AD)是一种常见的儿童皮肤病。多项研究评估了益生菌作为治疗AD的一种策略。我们旨在评估益生菌治疗儿童AD的有效性。
我们系统检索了PubMed/MEDLINE、Embase、Scopus、EBSCO、Web of Science和Cochrane图书馆数据库,以查找2010年1月1日至2023年1月1日期间评估益生菌治疗对AD儿科患者SCORAD值影响的随机对照试验(RCT),并与安慰剂组进行比较。使用Cochrane ROB 2.0评估偏倚风险和证据的确定性。
共纳入9项RCT的1000例患者的10项结果。其中3项结果在373例患者中作为二分变量进行分析。另外7项在627例患者中作为连续变量进行分析。二分变量随机效应模型的荟萃分析表明,益生菌组和对照组之间无显著差异[比值比(OR)=1.75,95%置信区间(CI)(0.70,4.35),p = 0.23,I² = 68%]。连续变量随机效应模型的荟萃分析表明,益生菌组和对照组之间存在显著差异[平均差(MD)=-4.24,95%CI(-7.78,-0.71),p = 0.002,I² = 71%]。连续变量亚组分析表明,儿童年龄、治疗持续时间和益生菌种类对SCORAD值的影响无统计学意义。
关于益生菌对AD儿科患者改善效果的证据有限。本研究表明单菌株益生菌治疗对AD有积极作用。限于纳入研究的数量和质量,这些结论有待高质量研究验证。